Diplomat Specialty Pharmacy® and Diplomat Specialty Infusion Group® are joining the Optum® family.

To learn more about what this means for you, visit our FAQ pages:

Specialty Pharmacy FAQ  •  Infusion Pharmacy FAQ

INFLECTRA®

Inflectra (infliximab-dyyb)

FDA INDICATION: Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis. Prescribing Information

DISTRIBUTOR: Pfizer

ROUTE OF ADMINISTRATION: Intravenous

FORM: Lyophilized

DOSAGE AND ADMINISTRATION:

Crohn’s disease: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. Some adult patients who initially respond to treatment may benefit from increasing the dose to 10 mg/kg if they later lose their response.

Pediatric Crohn’s disease: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.

Ulcerative colitis: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.

Rheumatoid arthritis: In conjunction with methotrexate, 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. Some patients may benefit from increasing the dose up to 10 mg/kg or treating as often as every 4 weeks.

Ankylosing spondylitis: 5 mg/kg at 0, 2 and 6 weeks, then every 6 weeks.

Psoriatic arthritis and plaque psoriasis: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.

HOW SUPPLIED: Each single use vial contains 100 mg of infliximab-dyyb for final reconstitution volume of 10 mL.

STORAGE REQUIREMENTS: Refrigerate at 2° to 8°C (36° to 46°F).

OTHER WEBSITES:  Pfizer EnCompass